Schizophrenia and neuropsychiatric disorders
Oryzon Genomics S.A. is involved in clinical research on schizophrenia, with a focus on negative symptoms and cognitive impairment in adult patients.
- Negative symptom burden
- Cognitive dysfunction
- Adult psychiatric populations
The sponsor’s portfolio includes studies centered on neuropsychiatric symptom domains that affect daily functioning and clinical outcomes.
Hematology and myeloproliferative disease
Its research activity includes essential thrombocythemia, particularly in patients who are resistant or intolerant to prior therapy, with attention to abnormal platelet counts and disease control.
- Essential thrombocythemia
- Platelet count abnormalities
- Treatment-resistant disease
This area reflects an interest in myeloproliferative neoplasms and the management of persistent hematologic abnormalities in adults.
Sickle cell disease
The sponsor is also studying sickle cell disease, extending its hematology program into inherited red blood cell disorders with significant clinical burden.
- Sickle cell disease
- Inherited blood disorders
- Adult patient care
These studies place emphasis on disease areas where chronic hematologic dysfunction and complication risk are central therapeutic concerns.
Healthy volunteer pharmacology
Oryzon Genomics S.A. also supports research in healthy male participants to characterize absorption, distribution, metabolism, and excretion of an investigational compound.
- Healthy volunteers
- Pharmacokinetics
- Drug disposition
This work contributes to understanding how the sponsor’s compounds behave in the body alongside its disease-focused programs.
